New triple therapy shows promise in shrinking advanced stomach tumors before surgery

NCT ID NCT06461910

First seen Mar 06, 2026 · Last updated May 14, 2026 · Updated 13 times

Summary

This study tests whether adding an immunotherapy drug (anti-PD-1) and an immune booster (thymalfasin) to standard chemotherapy (SOX) before surgery can help people with stage III stomach or gastroesophageal junction cancer. About 30 adults aged 18-75 will receive the combination, then have surgery to remove the tumor. The main goal is to see how many patients have no cancer cells left in the removed tissue (pathological complete response).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Hospital of Nanjing Medical University

    RECRUITING

    Nanjing, Jiangsu, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.